An 8.26M-share stake in Viridian Therapeutics (VRDN) spans a fund and separately managed accounts.
Paradigm BioCapital Advisors LP, its general partner, and Senai Asefaw, M.D., have reported a beneficial ownership of 8,257,672 common shares (7.3%) in Viridian Therapeutics (VRDN) as of September 30, 2026. This stake includes shares held by Paradigm BioCapital International Fund Ltd., which independently reported 7,278,105 shares (6.4%). The total percentages are based on 113,292,269 shares outstanding as of August 3, 2026, with the reporting persons' figures overlapping rather than being additive.
T. Rowe Price reports 5.12M shares in Viridian Therapeutics (VRDN).
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 5,123,592 shares, or 4.5%, of Viridian Therapeutics, Inc. (VRDN) common stock as of September 30, 2026. The filing indicates sole voting power over 5,123,546 shares and sole dispositive power over 5,123,592 shares, while explicitly denying that the filing constitutes an admission of beneficial ownership.
Is Viridian Therapeutics (VRDN) Undervalued Following Its Promising VRDN 008 Phase 1 Results?
Viridian Therapeutics (VRDN) is gaining attention after reporting strong Phase 1 data for VRDN-008, an FcRn inhibitor, leading to a significant increase in its share price. Despite this rally, the company's shares are still considered undervalued by analysts, trading below target prices and some intrinsic value estimates. However, an alternative perspective suggests VRDN looks expensive based on its price-to-book ratio compared to industry peers.
How Phase 1 Success At Viridian Therapeutics (VRDN) Has Changed Its Investment Story
Viridian Therapeutics reported positive Phase 1 results for VRDN-008, an FcRn inhibitor showing deep and sustained IgG reduction. This success strengthens the company's pipeline beyond its thyroid eye disease franchise, suggesting a shift towards broader autoimmune indications. While Lumvoa uptake remains a near-term focus, VRDN-008's potential for extended dosing and at-home administration offers future catalysts for revenue diversification and long-term growth, despite current widening net losses.
Wells Fargo maintains Viridian Therapeutics at Overweight, raises price target to $39 from $34
Wells Fargo has reiterated its "Overweight" rating for Viridian Therapeutics and increased its price target to $39 from $34, representing a 14.7% rise. This new target suggests a potential upside of 29.2% from the stock's closing price on November 9th. Other analysts have recently issued price targets ranging from $33 to $54 for the company.
A 4.88 million-share stake in Viridian Therapeutics (VRDN) is reported by State Street.
State Street Corporation reported a beneficial ownership of 4,876,395 common shares in Viridian Therapeutics (VRDN), representing 4.3% of the class as of September 30, 2026. The filing indicates that State Street holds shared voting power over 4,633,744 shares and shared dispositive power over 4,876,395 shares. This passive investment disclosure was made through a SCHEDULE 13G filing.
Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing
Viridian Therapeutics Inc. reported positive Phase 1 clinical trial results for VRDN-008, a potential subcutaneous treatment for autoimmune and rare diseases, leading to a rally in its stock. The therapy demonstrated sustained IgG antibody reduction for eight weeks, supporting a future dosing schedule of once every eight weeks. The company plans to advance VRDN-008 into pivotal development, targeting a registrational trial launch in mid-2027 for myasthenia gravis and other autoantibody-mediated autoimmune diseases.
Viridian Therapeutics gains long-term potential from extended-acting FcRn drug, Jefferies says
Jefferies believes Viridian Therapeutics' extended-acting FcRn inhibitor, VRDN-008, has best-in-class potential due to its eight-week dosing schedule, which offers a competitive advantage over existing treatments for generalized Myasthenia Gravis (gMG). The firm sees significant market share potential for Viridian, despite the 30-minute administration time using an on-body injector. Jefferies has maintained a $35 price target, projecting pivotal data by late 2029 and approval by 2031, with further opportunities in other autoimmune diseases.
Form 8K Viridian Therapeutics Inc For: 9 November By Investing.com
This article announces that Viridian Therapeutics Inc. filed a Form 8K on November 9, 2026. The filing is brief, providing essential company information and a link to view the complete document. The stock symbol VRDN is mentioned with a 5.21% increase.
VRDN: Viridian Therapeutics Inc. filed SEC Form 8-K: Regulation FD...
Viridian Therapeutics Inc. filed an SEC Form 8-K, reporting positive Phase 1 data for VRDN-008, a half-life extended FcRn inhibitor. The drug showed a 74% peak IgG reduction through eight weeks in healthy volunteers, with a half-life of 15 to 18 days. The company plans to initiate pivotal trials for myasthenia gravis in mid-2027, subject to regulatory feedback.
VRDN: Viridian Therapeutics Inc. filed SEC Form 8-K: Regulation FD...
Viridian Therapeutics Inc. filed an SEC Form 8-K disclosing positive Phase 1 data for VRDN-008, an FcRn inhibitor, in healthy volunteers. The drug demonstrated a 74% peak IgG reduction and an extended half-life of 15 to 18 days. The company plans to initiate a pivotal trial in myasthenia gravis by mid-2027, subject to regulatory feedback.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
Viridian Therapeutics (NASDAQ:VRDN) reported strong third-quarter results, with revenues significantly exceeding analyst forecasts and losses per share being smaller than anticipated. Following these results, analysts have substantially increased their revenue forecasts for 2027 and reduced their estimated loss per share, indicating a positive shift in sentiment. The price target for Viridian Therapeutics has also been raised, reflecting an improving intrinsic value of the business and expectations of faster growth than the industry average.
Viridian Therapeutics, Inc. (VRDN) stock price, news, quote and history
This article provides a detailed overview of Viridian Therapeutics, Inc. (VRDN), including its current stock price, recent performance, key financial statistics, and an company overview. It highlights the company's focus on developing treatments for serious and rare diseases, particularly thyroid eye disease (TED) and Graves' disease, and includes analyst insights and performance comparisons against the S&P 500.
Healthy volunteers took part in the drug study Viridian will discuss Nov. 9
Viridian Therapeutics (VRDN) announced it will host a conference call on November 9, 2026, to present data from the VRDN-008 Phase 1 clinical trial conducted in healthy volunteers. The company will also discuss its development plans for its neonatal Fc receptor (FcRn) portfolio during this event.
Leerink Partners maintains Viridian Therapeutics at Outperform, raises price target to $54 from $50
Leerink Partners has reiterated its "Outperform" rating for Viridian Therapeutics and increased its price target to $54 from $50, representing an 8.0% hike. This new price target suggests an 85.9% upside from the stock's closing price of $29.05 on November 4. Other analysts have also recently maintained positive ratings on Viridian Therapeutics with price targets ranging from $33 to $42.
Truist Securities maintains Viridian Therapeutics at Buy
Truist Securities has maintained its "Buy" rating for Viridian Therapeutics and increased its price target from $39 to $42, representing a 7.7% increase and implying a 44.6% upside from the previous day's closing price. This move aligns with other recent analyst actions, which also show several firms maintaining "Overweight" or "Outperform" ratings with price targets ranging from $33 to $42.
What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call
Viridian Therapeutics reported strong Q3 earnings for its thyroid eye disease treatment, Lumvoa, exceeding expectations with $24.7 million in net product revenue in its first quarter on the market. The company ended the quarter with over $955 million in cash, stating it has sufficient resources to fund operations through profitability. Viridian is also progressing with its pipeline, including a biologics license application for elegrobart and upcoming phase 1 trials for VRDN-008 and VRDN-292.
Viridian Therapeutics Posts $24.7 Million in Lumvoa Net Product Revenue for Q3 2026
Viridian Therapeutics reported $24.7 million in Lumvoa net product revenue for the third quarter of 2026, contributing to a total revenue of $25.752 million. The company recorded a GAAP net loss per share of $0.81 on both basic and diluted bases for the period ending September 30, 2026. These financial results were released on November 4, 2026.
Stifel raises Viridian Therapeutic stock price target on strong Lumvoa launch
Stifel has increased its price target for Viridian Therapeutics (NASDAQ:VRDN) to $43.00 from $40.00, reiterating a Buy rating, following the strong launch of Lumvoa for thyroid eye disease. The drug's first full quarter saw revenue of $24.7 million, significantly exceeding expectations, with over 100 patients on therapy by quarter-end. This success has led Stifel to raise its revenue estimates for Q4 2026 and 2027, with the stock surging 79% in the past six months.
Viridian Therapeutics Q3 2026 Earnings Call Transcript
Viridian Therapeutics announced strong Q3 2026 results, with Lynvoa generating $24.7 million in net product revenue and over 100 patients on therapy for thyroid eye disease. The company is advancing its pipeline, including BLA submission for Allegribart in Q1 2027 and a Phase 1 trial for VRDN-292, maintaining a robust financial position with over $955 million in cash. Management expressed confidence in Lynvoa's market penetration and the potential for future growth from its autoimmune disease portfolio.
Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
Viridian Therapeutics reported strong third-quarter 2026 financial results, with Lumvoa™ generating $24.7 million in net product revenue and over 100 patients on therapy. The company is advancing its pipeline, including Elegrobart's Biologics License Application submission on track for Q1 2027 and expected phase 1 data disclosure for VRDN-008 in Q4 2026. Viridian's cash position of $955.2 million is projected to fund current business plans through profitability.
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates
Viridian Therapeutics (VRDN) reported a narrower-than-expected Q3 loss of $0.81 per share, beating the Zacks Consensus Estimate of a $1.01 loss. The company also surpassed revenue estimates, posting $25.75 million against an expected $5.75 million. Despite the positive earnings surprise, Viridian Therapeutics' shares have declined 19.2% year-to-date, underperforming the S&P 500.
Viridian Therapeutics Q3 2026 Earnings Call Is Live
Viridian Therapeutics has commenced its Q3 2026 earnings call, where executives will discuss the latest financial results and answer questions from Wall Street analysts. This event is crucial for investors following VRDN, as management commentary on future demand, margins, or capital spending can significantly impact market perception. The call provides an opportunity to gain insights into the company's performance beyond the initial earnings release.
Viridian Therapeutics, Inc. (VRDN) Tops Q3 EPS by 21c
Viridian Therapeutics, Inc. (VRDN) announced its Q3 earnings, reporting an EPS of ($0.81), which was $0.21 better than the analyst estimate of ($1.02). The company's revenue for the quarter came in at $25.75 million, significantly exceeding the consensus estimate of $4.68 million. The stock price reacted positively to the news, rising by 11.41% on the day.
With $24.7M in drug sales, Viridian Therapeutics (VRDN) posts a wider quarterly loss.
Viridian Therapeutics (VRDN) reported a widened net loss of $101.209 million in Q3 2026, compared to $34.599 million a year earlier, despite generating $25.752 million in revenue, primarily from $24.671 million in sales of its newly FDA-approved drug, veligrotug. The company's nine-month operating cash use was $317.751 million, and it expects its $955.2 million in cash, cash equivalents, and marketable securities to fund operations for at least 12 months. Viridian is also advancing other product candidates, including elegrobart for Thyroid Eye Disease and FcRn inhibitors for autoimmune disorders.
Learn Why The Bull Case For Viridian Therapeutics Stock Could Change Following FDA Approval
Viridian Therapeutics received FDA approval in June 2026 for Lumvoa, targeting the US$2 billion thyroid eye disease market, transitioning the company from a development-stage to a commercial business. This approval shifts the focus to Lumvoa's commercial execution, including payer access and sales force effectiveness, with analysts projecting significant revenue and earnings growth by 2029. However, operational risks like slower-than-expected rollout or higher costs could challenge these aggressive assumptions, potentially impacting the stock's valuation.
Learn Why The Bull Case For Viridian Therapeutics Stock Could Change Following FDA Approval
Viridian Therapeutics secured FDA approval for Lumvoa in June 2026, launching it into the US$2 billion thyroid eye disease market. This approval shifts the company's focus from development to commercial execution, with future growth depending on Lumvoa's market penetration and the company's path to profitability. Analysts project significant revenue and earnings growth by 2029, though alternative, more cautious forecasts also exist.
Viridian Therapeutics, Inc. (VRDN) Seasonal returns chart
The article displays a seasonal returns chart for Viridian Therapeutics, Inc. (VRDN), showing the average monthly price return between 2016 and 2026. It also provides current stock information, including the real-time Nasdaq price and after-hours trading data. The page focuses on financial data and charting for the company's stock performance.
Is Viridian Therapeutics (VRDN) Cheap After FDA Approval Of Lumvoa?
Viridian Therapeutics (VRDN) has received FDA approval for Lumvoa, shifting focus to its commercial launch for Thyroid Eye Disease. While the stock has seen recent gains, it remains down year-to-date and analysts have mixed views on its valuation. Some consider it undervalued at $36.75 compared to its current price, while others see it as expensive based on its 38.4x sales multiple.
How Investors May Respond To Viridian Therapeutics (VRDN) FDA Approval For TED Treatment
Viridian Therapeutics recently received FDA approval for Lumvoa, its treatment for Thyroid Eye Disease (TED), positioning it to enter an underpenetrated $2 billion market. This approval is crucial for the company's shift from a loss-making biotech to a commercial rare disease player, with analysts forecasting significant revenue and earnings growth by 2029. The key for investors will be the successful commercial execution of Lumvoa and the progress of its pipeline assets like elegrobart.
Viridian Therapeutics, Inc. Estimates – NASDAQ:VRDN
This article provides an overview of Viridian Therapeutics, Inc. (NASDAQ:VRDN) financial data and analyst estimates available on TradingView. It directs users to explore reported financial data and compare actual results with average, high, and low estimates across income statements, balance sheets, and cash flow statements, emphasizing that the information is not investment advice.
Viridian Therapeutics, Inc. Estimates – TRADEGATE:1S1
This article provides access to financial estimates for Viridian Therapeutics, Inc. (TRADEGATE: 1S1) on the TradingView platform. Users can explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and visualization of trends over time.
Viridian Therapeutics to report Q3FY26 results on November 4
Viridian Therapeutics announced it will release its third quarter fiscal 2026 financial results before the market opens on Wednesday, November 4, 2026. A conference call is scheduled for 8:00 am ET on the same day to discuss the results and provide a business update. The biotechnology company specializes in discovering and developing medicines for autoimmune and rare diseases, with key pipeline assets including Lumvoa, an FDA-approved treatment for thyroid eye disease (TED), and Elegrobart, a late-stage investigational subcutaneous therapy for TED.
Press Release: Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
Viridian Therapeutics announced it will report its third-quarter 2026 financial results on November 4, 2026. The company will also provide a corporate update and host a webcast and conference call to discuss the results. Management will be available for a question-and-answer session following the prepared remarks.
Viridian Therapeutics presents 54 percent trial data for VRDN stock
Viridian Therapeutics announced phase 3 REVEAL-1 trial data for its drug Elegrobart, showing a 54% proptosis responder rate compared to 18% for placebo in active thyroid eye disease patients. The company's stock, VRDN, was trading at EUR 18.50 on October 20, 2026, ahead of its next earnings report scheduled for November 4, 2026. This clinical data, along with analyst target increases, is critical for the company's valuation and path to commercialization.
Viridian Therapeutics presents phase 3 data: what it means for Viridian Therapeutics stock
Viridian Therapeutics presented positive Phase 3 REVEAL-1 data for elegrobart, showing a 54% responder rate versus 18% for placebo in active thyroid eye disease. This clinical success is crucial for the company, as it is still heavily dependent on clinical execution and future product launches due to high development spending and limited current revenue. Upcoming events include Q3 2026 results on November 4, 2026, and a planned biologics license application in Q1 2027.
Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base
Viridian Therapeutics (VRDN) stock has gained 64.3% in the last three years, but its current price-to-sales (P/S) ratio of 30.3x is significantly higher than the industry average. This suggests the stock may be overvalued relative to its sales performance, especially since the company is still reporting free cash flow losses. While some narratives suggest Viridian Therapeutics is undervalued based on market potential, its current valuation appears stretched.
Wells Fargo keeps Buy rating for Viridian Therapeutics stock at USD 31 target
Wells Fargo maintained a Buy rating for Viridian Therapeutics (VRDN) with a USD 31.00 target price on October 14, 2026. The biotechnology company, focused on autoimmune and rare diseases, reported second-quarter 2026 revenue of USD 284 thousand and a GAAP net loss of USD 127.12 million. Other analysts, LifeSci Capital and RBC Capital, also hold Buy ratings with higher price targets.
Wells Fargo keeps Buy rating for Viridian Therapeutics stock at USD 31 target
Wells Fargo has reaffirmed its Buy rating for Viridian Therapeutics (VRDN) stock, setting a price target of USD 31.00. This follows Viridian's Q2 2026 revenue of USD 284 thousand and a GAAP net loss of USD 127.12 million, with the company focusing on treatments for autoimmune and rare diseases, particularly thyroid eye disease. Other analysts, LifeSci Capital and RBC Capital, have also maintained Buy ratings with targets of USD 35.00 and USD 38.00, respectively.
Diluted shares outstanding of Viridian Therapeutics, Inc. – HAN:1S1
This article from TradingView provides a financial data point for Viridian Therapeutics, Inc. (HAN:1S1) listed on the Hannover Stock Exchange. Specifically, it focuses on the company's diluted shares outstanding, noting that the market is closed and no trades have occurred for this specific data point. The content confirms the data is made by humans and sourced from ICE Data Services and FactSet.
Viridian Therapeutics (NasdaqCM:VRDN) Aktienprognose & Analystenprognosen
Viridian Therapeutics (VRDN) is projected to achieve significant annual growth in earnings (63.8%) and revenue (52.3%), with EPS expected to grow by 64.7% per year. Despite strong growth forecasts, the company is anticipated to remain unprofitable with a negative return on equity in three years. Recent analyst revisions have decreased 2026 revenue forecasts, yet the consensus price target remains unchanged at US$36.75, suggesting potential upside.
How (VRDN) Movements Inform Risk Allocation Models
This article analyzes Viridian Therapeutics Inc. (NASDAQ: VRDN) using AI models, suggesting a near-term neutral sentiment amidst mid and long-term weakness. It identifies an exceptional 112.2:1 risk-reward setup and provides specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
RBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)
RBC Capital maintained a Buy rating on Viridian Therapeutics (VRDN) with a price target of $38.00, following an earlier Buy rating from LifeSci Capital. The company recently reported Q2 revenue of $284 thousand and a GAAP net loss of $127.12 million. Corporate insider sentiment for VRDN is negative, with an increase in insider selling over the last quarter.
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $38
RBC Capital has reiterated its Buy rating for Viridian Therapeutics (VRDN.US), maintaining a target price of $38. This indicates the firm's continued confidence in the company's stock performance.
Viridian Therapeutics stock weighs Lumvoa uptake against losses
Viridian Therapeutics is evaluating the initial commercial success of its drug Lumvoa for thyroid eye disease against a Q2 2026 loss of USD 1.05 per share. RBC raised its price target for Viridian to USD 38.00, citing stronger-than-anticipated commercial rollout, while the company's financial performance still reflects its clinical-stage biotechnology status. Investors are watching to see if Lumvoa's launch will significantly increase commercial revenue and offset ongoing operational losses.
Total debt of Viridian Therapeutics, Inc. – HAN:1S1
This article provides financial information for Viridian Therapeutics, Inc. (1S1) listed on the Hannover Stock Exchange. It specifically highlights the company's total debt value over a given period, indicating changes in both absolute terms and percentages.
Discontinued operations of Viridian Therapeutics, Inc. – HAN:1S1
This article from TradingView states that Viridian Therapeutics, Inc. (HAN:1S1) has discontinued its operations. The brief update provides no further details on the reasons or implications of this discontinuation.
Does Strong Lumvoa Launch Change The Bull Case For Viridian Therapeutics Stock (VRDN)?
RBC Capital Markets reported a stronger-than-expected commercial launch for Viridian Therapeutics' thyroid eye disease drug, Lumvoa. This early traction suggests solid demand, which could help the company scale operations and impact its investment narrative, though Viridian remains loss-making. Analysts previously projected significant revenue and earnings growth by 2029 for Lumvoa and elegrobart, and this new information may influence future forecasts.
Viridian Therapeutics (NasdaqCM:VRDN) Stock Forecast & Analyst Predictions
Viridian Therapeutics (NasdaqCM:VRDN) is forecast to grow earnings by 63.7% and revenue by 52% per annum, with EPS expected to increase by 64.6%. The company, which recently received FDA approval for Lumvoa for Thyroid Eye Disease (TED), is projected to become profitable within the next three years, potentially breaking even in 2028. Despite positive clinical trial results for its TED treatments, analysts have revised revenue estimates downward, and the company faces risks related to shareholder dilution and share price volatility.
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $38
RBC Capital has reiterated its Buy rating on Viridian Therapeutics (VRDN.US) and increased its price target for the company's stock to $38. This adjustment reflects continued confidence in the pharmaceutical company's future performance.